Silo Pharma files patent application with USPTO for SPC-14

Silo Pharma (SILO) announced the filing of a patent application with the U.S. Patent and Trademark Office focused on the neurology drug SPC-14, an intranasal compound for the treatment of Alzheimer’s disease exclusively licensed to Silo Pharma from Columbia University. The patent, titled “Compositions and Methods for the Treatment of Alzheimer’s Disease and Other Neurogenerative Disease,” covers SPC-14’s novel mechanism of action for targeting glutamate receptor NDMAR and serotonin 5-HT4 to address cognitive and neuropsychiatric symptoms in AD. By targeting the two receptor molecules, the drug has shown efficacy against luteinizing hormone in attenuating learned helplessness, perseverative behavior, and hyponeophagia.